Tag Archives: Otsuka

November, 2018

30 November
Lundbeck and Otsuka Announce Positive Phase 2 Data for Combination Treatment of Brexpiprazole and Sertraline in Post-Traumatic Stress Disorder

Valby, Denmark and Tokyo, Japan, 30 November 2018 – H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) announced today the achievement of positive clinical results (in intention-to-treat population) as measured by the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) total score change from baseline compared to placebo, when brexpiprazole and …
Share

26 October
FDA Grants Priority Review to Taiho Oncology’s sNDA for Lonsurf for Treatment of GEJ Adenocarcinoma

PRINCETON, N.J., October 25, 2018 – Taiho Oncology, Inc. today announced that the United States Food and Drug Administration (FDA) has accepted and granted priority review for the supplemental New Drug Application (sNDA) for LONSURF® (trifluridine/tipiracil, TAS-102) as a treatment for patients with previously treated, advanced or metastatic gastric adenocarcinoma, including …
Share

2 August
Astex and Otsuka Announce that Guadecitabine Fails to Meet Endpoints in Late-Stage AML Study

otsuk PLEASANTON, Calif. & TOKYO–(BUSINESS WIRE)–Astex Pharmaceuticals, a member of the Otsuka group of companies, and Otsuka Pharmaceutical Co. Ltd., announce top-line results from the ASTRAL-1 study evaluating the efficacy and safety of guadecitabine (SGI-110) in adults with previously untreated AML who are not eligible for intensive induction chemotherapy. The …
Share

11 July
Otsuka to Expand its Pipeline of Antibody-Based Therapies through its $430 Million Acquisition of Visterra

TOKYO & WALTHAM, Mass.–(BUSINESS WIRE)–Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Visterra, Inc. (Visterra) announce that they have entered into a definitive merger agreement pursuant to which Otsuka will acquire Visterra for approximately USD 430 million in an all-cash transaction. The Otsuka and Visterra boards of directors have approved the transaction. …
Share

25 April
FDA Approves Otsuka’s Jynarque as the First Treatment to Slow Kidney Function Decline in Patients at Risk of Rapidly Progressing ADPKD

TOKYO–(BUSINESS WIRE)–Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that the U.S. Food and Drug Administration (FDA) has approved JYNARQUE™ (tolvaptan) as the first drug treatment to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD). ADPKD is a genetic disease with consequences that can lead …
Share

15 December
GW Pharma Reacquires Full Rights to Develop and Commercialize Sativex in the US

London, UK, 13 Dec 2017: GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announces the termination of its previous license agreement with Otsuka Pharmaceutical Co., Ltd. in relation to Sativex®(nabiximols) in the U.S. …
Share

27 October
GW and Otsuka Announce Phase 3 Results from its Sativex Trials

LONDON and PRINCETON, N.J., Oct. 27, 2015 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (NASDAQ:GWPH) (AIM:GWP) (“GW”) and Otsuka Pharmaceutical Development & Commercialization, Inc. (“Otsuka”), today reported top-line results from the remaining two Phase 3 trials for the investigational product Sativex® in the treatment of pain in patients with advanced cancer …
Share